Review
Microbiology
Jim Manos
Summary: The aim of antimicrobial treatment for bacterial infections in CF lung is to improve infection outcomes for patients. Current treatments include antibiotics with physical therapy, but there are challenges such as bacterial survival in biofilm aggregates. Emerging treatments involving novel compounds or bacteriophages show promise in disrupting biofilm matrix and improving antibiotic access.
Review
Cell Biology
Francesca Saluzzo, Luca Riberi, Barbara Messore, Nicola Ivan Lore, Irene Esposito, Elisabetta Bignamini, Virginia De Rose
Summary: Cystic Fibrosis (CF) is a genetic disease caused by mutations in the CFTR gene, leading to imbalances in the airway microenvironment and increased susceptibility to infections. CFTR modulators have shown promise in improving airway infections, but their long-term effects remain to be fully understood.
Review
Pharmacology & Pharmacy
Katelin M. Allan, Nigel Farrow, Martin Donnelley, Adam Jaffe, Shafagh A. Waters
Summary: Prognosis of CF patients varies significantly despite advances in targeted therapies improving CFTR function. Lung tissue destruction remains a major cause of morbidity and mortality. Challenges in gene therapy and cell-based therapy for CF treatment need to be addressed through further research and development.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Pediatrics
Thomas W. Laudone, Lauren Garner, Charissa W. Kam, Charles R. Esther, Cameron J. McKinzie
Summary: Respiratory infections caused by non-tuberculous mycobacteria (NTM) are a major challenge for patients with cystic fibrosis (CF), with only 50% to 60% of patients achieving culture conversion despite lengthy treatment regimens. New or alternative antibiotic regimens have been described for CF patients with NTM pulmonary disease (NTM-PD) who do not respond to standard therapies, providing new options for those with toxicities or drug interactions.
PEDIATRIC PULMONOLOGY
(2021)
Review
Medicine, Research & Experimental
Shijing Jia, Jennifer L. Taylor-Cousar
Summary: Cystic fibrosis (CF) is a genetic disease that affects multiple organ systems and can lead to various complications. Traditional treatments focused on managing the symptoms of each affected system. However, the development of modulator therapies targeted at specific genetic mutations has significantly improved the lives and prognosis of CF patients.
ANNUAL REVIEW OF MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Christelle Bergeron, Andre M. Cantin
Summary: Rare diseases affect 400 million individuals globally, and cystic fibrosis, a genetic disease, has seen advancements in potential therapies that aim to restore CFTR function, showing promise in improving the lives of patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Madalena C. Pinto, Margarida C. Quaresma, Iris A. L. Silva, Violeta Railean, Sofia S. Ramalho, Margarida D. Amaral
Summary: SLC26A9 is a constitutively active Cl- transporter that contributes to epithelial Cl- secretion and is implicated in respiratory disorders such as CF. Studies have shown that enhancing SLC26A9 expression can increase CFTR function and response to CFTR correctors, suggesting its potential as a therapeutic target for CF.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Infectious Diseases
Jaideep Vazirani, Thomas Crowhurst, C. Orla Morrissey, Gregory Snell
Summary: Cystic fibrosis is a genetic multisystem disease, and lung transplantation is an effective treatment option. However, managing recurrent infections and balancing immune suppression in this setting can be difficult. Infections are a major contributor to post-transplant mortality, with multidrug-resistant organisms posing a significant threat to survival.
INFECTION AND DRUG RESISTANCE
(2021)
Review
Clinical Neurology
Miriam Mistretta, Andrea Farini, Yvan Torrente, Chiara Villa
Summary: Developing drugs that can cross the blood-brain barrier is a challenge for treating neurodegenerative disease. The use of nanoparticle-based systems shows potential in overcoming this difficulty, with the example of Friedreich's ataxia. Neurodegenerative diseases are a global health burden, and traditional interventions have limitations in reaching the brain. Nanosystems offer a promising therapeutic approach by delivering drugs and improving bioavailability. This review highlights the use of nanosystems in targeting molecular pathways involved in neurodegenerative diseases, with Friedreich's ataxia as an example.
Editorial Material
Immunology
Nathaniel C. Warner, Luther A. Bartelt, Anne M. Lachiewicz, Kathleen M. Tompkins, Melissa B. Miller, Kevin Alby, Melissa B. Jones, Amy L. Carr, Jose Alexander, Andrew B. Gainey, Robert Daniels, Anna-Kathryn Burch, David E. Brown, Michael J. Brownstein, Faiqa Cheema, Kristin E. Linder, Ryan K. Shields, Sarah Longworth, David van Duin
Summary: Treatment options for Achromobacter xylosoxidans are limited, but clinical response was observed after cefiderocol treatment. However, microbiologic relapse was common after treatment, notably without emergence of resistance.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Chemistry, Physical
Honghua Hu, Nicole Clothier, Anita Jacombs, Karen Mckay, Anand K. Deva, Karen Vickery
Summary: This study suggests that toothbrushes of children with cystic fibrosis may harbor biofilms of pathogens, which can potentially cause lung re-infection even after antibiotic treatment.
Review
Biochemistry & Molecular Biology
Giulia Gorrieri, Federico Zara, Paolo Scudieri
Summary: SLC26A9, a member of the solute carrier family 26 (SLC26), is involved in ion transport mechanisms. It has emerged as one of the interesting alternative targets for cystic fibrosis (CF) treatment, although there are still controversies regarding its contribution and potential. This review summarizes various studies related to SLC26A9, aiming to reconcile them and highlight the current understanding and knowledge gap regarding its role in human lung physiology and CF treatment.
Review
Genetics & Heredity
Annalucia Carbone, Pamela Vitullo, Sante Di Gioia, Massimo Conese
Summary: Cystic fibrosis is a genetic disease caused by mutations in the CFTR gene. The severity of the disease in patients is influenced by genetic and environmental factors. Lung inflammation plays a crucial role in cystic fibrosis lung disease, and CFTR modulator therapies can improve the inflammatory process, but individual responses may vary.
Review
Biochemistry & Molecular Biology
Devi Jaganathan, Emanuela M. Bruscia, Benjamin T. Kopp
Summary: Cystic fibrosis is a disease caused by mutations in the CFTR gene, resulting in chronic inflammation and lung function decline. Macrophages play a crucial role in CF and the mutant CFTR affects phagocytosis, which is linked to disease progression. A better understanding of the interaction between CFTR and macrophages during phagosome formation could contribute to the development of new therapeutic strategies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Medicine, Research & Experimental
Yanmei Zhang, Xin Hu, Jing Shang, Wenhui Shao, Liming Jin, Chunshan Quan, Jun Li
Summary: Pathogenic infections pose major threats to global public health due to the abuse of antibiotics and the resulting multidrug resistance. The development of novel, efficient, and biosafe antibiotic alternatives is urgently needed. Nanozymes have emerged as promising alternatives for combating bacterial infections, particularly through multimodal synergistic therapies that offer novel disinfection pathways.
Article
Multidisciplinary Sciences
Mackenzie Thornbury, Jacob Sicheri, Patrick Slaine, Landon J. Getz, Emma Finlayson-Trick, Jamie Cook, Caroline Guinard, Nicholas Boudreau, David Jakeman, John Rohde, Craig McCormick
Article
Virology
Nathalie Grandvaux, Craig McCormick
Article
Cell Biology
Lea Gaucherand, Brittany K. Porter, Rachel E. Levene, Emma L. Price, Summer K. Schmaling, Chris H. Rycroft, Yuzo Kevorkian, Craig McCormick, Denys A. Khaperskyy, Marta M. Gaglia
Article
Virology
Eric S. Pringle, Carolyn-Ann Robinson, Craig McCormick
JOURNAL OF VIROLOGY
(2019)
Article
Immunology
Zheng Pang, Renee Raudonis, Craig McCormick, Zhenyu Cheng
INFECTION AND IMMUNITY
(2020)
Article
Virology
Eric S. Pringle, Jaime Wertman, Nicole Melong, Andrew J. Coombs, Andrew L. Young, David O'Leary, Chansey Veinotte, Carolyn-Ann Robinson, Michael N. Ha, Graham Dellaire, Todd E. Druley, Craig McCormick, Jason N. Berman
Review
Virology
Benjamin P. Johnston, Craig McCormick
Article
Microbiology
Benjamin P. Johnston, Eric S. Pringle, Craig McCormick
Article
Virology
Mir Munir A. Rahim, Brendon D. Parsons, Emma L. Price, Patrick D. Slaine, Becca L. Chilvers, Gregory S. Seaton, Andrew Wight, Daniel Medina-Luna, Sayanti Dey, Shannen L. Grandy, Lauryn E. Anderson, Natalia Zamorano Cuervo, Nathalie Grandvaux, Marta M. Gaglia, Alyson A. Kelvin, Denys A. Khaperskyy, Craig McCormick, Andrew P. Makrigiannis
JOURNAL OF VIROLOGY
(2020)
Review
Virology
Madeleine L. Stolz, Craig McCormick
Article
Virology
Patrick D. Slaine, Mariel Kleer, Brett A. Duguay, Eric S. Pringle, Eileigh Kadijk, Shan Ying, Aruna Balgi, Michel Roberge, Craig McCormick, Denys A. Khaperskyy
Summary: 6-TG and 6-TGo are effective host-targeted antivirals that trigger the unfolded protein response (UPR) and selectively disrupt the accumulation of viral glycoproteins, showing promise as broad antiviral agents against enveloped viruses.
JOURNAL OF VIROLOGY
(2021)
Article
Virology
Brett A. Duguay, Adrian Herod, Eric S. Pringle, Susan M. A. Monro, Marc Hetu, Colin G. Cameron, Sherri A. McFarland, Craig McCormick
Summary: This study demonstrates that photoactivated PhytoQuin can inactivate human coronaviruses, inhibit their replication, and alter their protein structure. The antiviral effect of PhytoQuin is light-dependent and remains effective at sub-cytotoxic doses of the photosensitizer. This expands the list of susceptible viruses.
Article
Microbiology
Eric S. Pringle, Brett A. Duguay, Maxwell P. Bui-Marinos, Rory P. Mulloy, Shelby L. Landreth, Krishna Swaroop Desireddy, Stacia M. Dolliver, Shan Ying, Taylor Caddell, Trinity H. Tooley, Patrick D. Slaine, Stephen L. Bearne, Darryl Falzarano, Jennifer A. Corcoran, Denys A. Khaperskyy, Craig McCormick
Summary: Reported the inhibitory effect of thiopurines on the replication of HCoV-OC43 and SARS-CoV-2 coronaviruses, and discovered defective Spike trafficking and processing as a result of 6-TG treatment.
Article
Cell Biology
Kathleen M. Attwood, Aaron Robichaud, Lauren P. Westhaver, Elizabeth L. Castle, David M. Brandman, Aruna D. Balgi, Michel Roberge, Patricia Colp, Sidney Croul, Inhwa Kim, Craig McCormick, Jennifer A. Corcoran, Adrienne Weeks
CELL DEATH & DISEASE
(2020)
Article
Engineering, Environmental
C. Carolina Ontiveros, Crystal L. Sweeney, Chris Smith, Sean MacIsaac, Sebastian Munoz, Ross Davidson, Craig McCormick, Nikhil Thomas, Ian Davis, Amina K. Stoddart, Graham A. Gagnon
ENVIRONMENTAL SCIENCE-WATER RESEARCH & TECHNOLOGY
(2020)
